A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma. - Kumagai K; Hosoda K; Katada C; Ishido K; Watanabe A; Wada T; Niihara M; Higuchi T; Sakuraya M; Washio M; Chuman M; Harada H; et al. (Journal of gastroenterology, 2026)